Skip to Main Content

Pacific Biosciences of California, a maker of DNA sequencing equipment that has seen its stock rise dramatically in recent years, said Tuesday that it will purchase Omniome, a smaller rival, for up to $800 million.

PacBio, as the firm is known, will offer $600 million, half in cash and half in stock, up front. It will pay another $200 million when and if  machines based on Omniome’s technology first ship to customers. In order to finance the deal, PacBio is selling $300 million in a private placement to existing investors.


The company also announced that it and its partner Invitae, a diagnostics company, intend to expand their collaboration to include Omniome’s technology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.